Abstract:GI complications in Spain.Methods: Setting: 10 general hospitals in Spain attending 3.000.000people.All patients hospitalized due to GI events with diagnostic codes registered in the Minimum Basic Data Set that describe GI complication events (AJG 2005) occurring at each participating hospital from Jan 1, 1996, to Dec 31, 2005, have been included in the study.All codes identifying either upper, lower or non-defined (e.g.gastrointestinal bleeding) sources of GI events have been validated.Results: A total of 30,498 patients had 34,544 events in 10 years.There were clear decreasing trends in the crude rate of upper GI events from 77/100,000 people in 1996 (59.6% of all GI events) to 39/100,000 people (39.9% of GI events) in 2005*, and increasing trends in the crude rate of lower GI events from 10 cases/100,000 people (7.9% of GI events) in 1996 to 27/100,000 people (27.9% of GI events) in 2005*.Occurrence of cases with non-specific codes was stable over time.Validation reviewing original clinical charts (6726 = 22% of all 30,498 patients) showed that the source of the event in patients with non-defined GI codes (n=4492) was located in the upper GI tract in 51% of cases, 28% in the lower GI tract whereas the rest remained undefined.This suggests that of all hospitalization due to GI events, 56% were upper GI events, 38% lower GI events and 6 % undefined in the year 2005.Data from validation review of charts revealed that compared to upper GI events, lower GI events were more severe (dead rate 5.5% vs 8.7%*), had longer duration of hospitalization (7.8±8.4 vs 11.5±13.9days*) and higher impact on resource utilization (Group related diagnosis weight= 1.3±1.2vs 1.9±2.2*).Overall, recorded NSAID/ASA use was higher in the elderly (> 65 y.o.), was similar in elderly men with either upper or lower GI events (36.7% vs 31.6%),but not in elderly women (42% vs 31.5%*).Conclusions: Over the last 10 years, there was a clear decreasing trend in the rates of hospitalizations due to upper GI complications in contrast with an increasing trend of lower GI complications.The clinical impact and severity of hospitalizations due to lower GI events were greater than those of upper GI events, and among the elderly, a third of lower GI events were associated with NSAID/ASA use.(*p <0.0001; chi-square test).

Meta-analysis of proton pump inhibitor for preventing recurrence of non-steroidal anti-inflammatory drags-induced ulcers

[Effects of Proton Pump Inhibitors on In-Stent Restenosis in Patients Receiving Clopidogrel: a Retrospective Analysis].

Long-term Use of Proton Pump Inhibitors is Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease

Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis

Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors

Meta-analysis of Influences on Intravenous Intermittent Administration and Continuous Infusion of Proton Pump Inhibitors on Prognosis of Patients with Peptic Ulcer Bleeding

Efficacy and Safety of Proton Pump Inhibitors in Patients With Coronary Artery Diseases Receiving Oral Antiplatelet Agents and/or Anticoagulants: A Systematic Review and Meta-Analysis

Effects of Proton-Pump Inhibitors on Functional Dyspepsia: A Meta-analysis of Randomized Placebo-Controlled Trials

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial

Similar Efficacy of Proton-Pump Inhibitors Vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin

Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis.

Systematic Review with Network Meta-Analysis: Comparative Effectiveness and Safety of Strategies for Preventing NSAID-associated Gastrointestinal Toxicity

Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-Blind, Randomised Trial.

Comparison of Prophylactic Effect of UGIB and Effects on Platelet Function Between PPIs and H2RAs Combined with DAPT: Systematic Review and Meta-Analysis.

Efficacy and Safety of Proton Pump Inhibitors (ppis) Plus Rebamipide for Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-Analysis

Impact of proton pump inhibitors on the risk of small bowel or colorectal bleeding: A systematic review and meta-analysis

Proton pump inhibitors are not associated with fundic gland polyps – a systematic review that takes into consideration all known confounders

114 Combination of a Cyclooxygenase (COX)-2 Selective NSAID and a Proton Pump Inhibitor for Prevention of Gastroduodenal Ulcers in Very High Risk Patients: A One-Year, Double-Blind, Randomized Trial

Research Progress and Clinical Use of Proton Pump Inhibitors

Prospective Randomized Trial of H-Pylori Eradication Versus Maintenance Omeprazole to Prevent Recurrent Upper Gastrointestinal Hemorrhage in High-Risk Aspirin and Non-Aspirin Nsaid Users.

Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis